Your browser doesn't support javascript.
loading
X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry.
O'Toole, Dana; Groth, Daniel; Wright, Hannah; Bonilla, Francisco A; Fuleihan, Ramsay L; Cunningham-Rundles, Charlotte; Sullivan, Kathleen E; Ochs, Hans D; Marsh, Rebecca; Feuille, Elizabeth.
Affiliation
  • O'Toole D; Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, Columbia University Irving Medical Center, New York-Presbyterian Morgan Stanley Children's Hospital, 3959 Broadway, New York, NY, 10036, USA. do2234@cumc.columbia.edu.
  • Groth D; Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, WA, USA.
  • Wright H; Immune Deficiency Foundation, Towson, MD, USA.
  • Bonilla FA; Northeast Allergy, Asthma & Immunology, Leominster, MA, USA.
  • Fuleihan RL; Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, Columbia University Irving Medical Center, New York-Presbyterian Morgan Stanley Children's Hospital, 3959 Broadway, New York, NY, 10036, USA.
  • Cunningham-Rundles C; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sullivan KE; Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Ochs HD; Department of Pediatrics, University of Washington and Seattle Children's Research Institute, Seattle, WA, USA.
  • Marsh R; Cincinatti Children's Hospital, Cincinnati, OH, USA.
  • Feuille E; Weill Cornell Medicine, New York, NY, USA.
J Clin Immunol ; 42(4): 827-836, 2022 05.
Article in En | MEDLINE | ID: mdl-35288819
ABSTRACT
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by mutations in the Bruton tyrosine kinase (BTK) gene leading to B lymphocyte deficiency and susceptibility to infection. A potential benefit of earlier diagnosis and treatment initiation on morbidity and mortality in XLA is incompletely understood. In the USIDNET Registry, we describe infection frequency and infection-related mortality in patients with XLA and their relationship to age of diagnosis and treatment initiation. Among the 231 XLA patients enrolled in the Registry, respiratory infections (N = 203, 88%) were the most commonly reported. Among those deceased (N = 20) where cause of death was known (N = 17), mortality was attributed to infection in most (N = 12, 71%). Chronic lung disease, often a consequence of repeated lower respiratory tract infection (LRTI), was also a frequent complication associated with mortality (N = 9, 53%). Age of diagnosis in years was lower for those without LRTI compared to those with (median 1.5 [IQR 0.5-3.3] vs. median 3.0 [IQR 1.0-5.0], p = 0.0026) and among living patients compared to deceased (median 1.8 [IQR 0.5-5.0] vs. median 2.7 [IQR 1.6-6.0], p = 0.04). Age at treatment initiation in years was lower among those without LRTIs compared to those with (median 1.0 [IQR 0.4-2.4] vs. median 2.8 [IQR 1.0-5.4], p = 0.0006). For every year increase in age at start of therapy, the odds of experiencing a LRTI was 1.216 (OR 1.216, 95% CI 1.048-1.411, p = 0.01). Given the expected finding of reduced LRTIs and mortality among those with earlier age at diagnosis, our study findings support inclusion of XLA in newborn screening programs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Agammaglobulinemia / Genetic Diseases, X-Linked Type of study: Diagnostic_studies Limits: Humans / Newborn Language: En Journal: J Clin Immunol Year: 2022 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Tract Infections / Agammaglobulinemia / Genetic Diseases, X-Linked Type of study: Diagnostic_studies Limits: Humans / Newborn Language: En Journal: J Clin Immunol Year: 2022 Document type: Article Affiliation country: Estados Unidos